research Treatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
Search
for
Sort by
Research
150-180 / 1000+ results 
research Efficacy and safety of bicalutamide in female hair loss: a review of the literature
Bicalutamide can reduce female pattern hair loss, especially in those with certain conditions, but has limited effects on other hair loss types.
research Baricitinib in pediatric chronic immune thrombocytopenia and associated autoimmune conditions: a case report
Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
research Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
research Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Circ 0020938 inhibits hair follicle stem cells proliferation via the miR-142-5p/DSG4 axis in cashmere goats
Circ 0020938 slows down hair growth in cashmere goats.
research (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production
The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Baricitinib as the first systemic treatment for severe alopecia areata
Baricitinib is effective as a treatment for severe hair loss.
research New Drugs: Eculizumab
Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
research The Impact of Lactobacillus-Rich Probiotic Nutrition on the Pharmacological Efficacy of Clotrimazole Delivered via Mucoadhesive Thermosensitive Hydrogels in Human Subjects with Recurrent Candidiasis
Combining probiotics, clotrimazole gel, and laser therapy improves treatment for recurrent yeast infections.
research Dienogest
Dienogest combined with ethinylestradiol is a highly effective birth control that improves menstrual symptoms and has manageable side effects.
research USE OF SPIRONOLACTONE IN COMBINATION WITH AN ORAL CONTRACEPTIVE IN TREATMENT OF HIRSUTISM
Spironolactone with an oral contraceptive improved hair growth in women with hirsutism.
research A phase I safety study of topical calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA).
Topical calcitriol is safe for preventing hair loss during chemotherapy.
research Worldwide Clinical and Real-World Exposure to Baricitinib
Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research Topical Minoxidil for Hair Loss in Women
research Clinical assessment of CL22209, a standardized proprietary extract of Asparagus racemosus, for mitigating vasomotor and menstrual symptoms in perimenopausal women: A randomized, double-blind, placebo-controlled study
CL22209, an Asparagus racemosus extract, safely reduces perimenopausal symptoms and balances hormones.
research An assessment of (1) cyproterone acetate and (2) ethinyl oestradiol and lynoestrenol (Minilyn) in the treatment of idiopathic hirsutism
Cyproterone acetate can effectively treat idiopathic hirsutism, but ethinyl oestradiol and lynoestrenol may not always reduce hair growth.
research CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane‐induced alopecia
CDK4/6 inhibitors can protect hair cells from chemotherapy damage.
research The senescence-like activity of BMS-470539 is associated with anti-fibrotic actions in models of dermal fibrosis
BMS-470539 reduces skin fibrosis and inflammation.
research Efficacy and tolerability of oral bicalutamide in forty postmenopausal women with female pattern hair loss: a retrospective study
Bicalutamide may improve hair growth in postmenopausal women with mild side effects.
research Clinical experience with Valette®
Valette® is an effective birth control pill that also reduces greasy hair and skin.
research Subclinical, early hair regrowth in alopecia areata patients under treatment with baricitinib detected by line‐field confocal optical coherence tomography evaluation
Baricitinib helps with early hair regrowth in people with alopecia areata.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
research Vesicular Carriers for Improved Oral Anticoagulation Competence of Rivaroxaban: In Vitro and In Vivo Investigation
Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.
research Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.